Brookline Capital Markets analyst L. Cann raised its Q2 2026 earnings per share (EPS) estimate for Moderna to ($1.97), a slight improvement from the previous forecast of ($1.98). The firm also provided forward guidance, projecting Q3 EPS at ($1.30), Q4 at ($2.16), full-year 2026 EPS at ($6.60), and FY2027 EPS at ($3.24). This update follows Moderna's recent earnings release where the company beat consensus estimates.
Moderna reported Q2 2026 EPS of ($1.97), surpassing analyst expectations of ($2.03) by $0.06. Revenue for the quarter reached $145.00 million, significantly exceeding the consensus estimate of $102.93 million and representing a 2.1% year-over-year increase. Despite the revenue beat, the company posted a negative net margin of 141.43% and a negative return on equity of 28.30%, reflecting the high costs associated with its mRNA platform development.
Institutional activity shows mixed signals regarding Moderna's stock. While several hedge funds like MUFG Securities EMEA and EverSource Wealth Advisors increased their stakes, insider selling remains notable. Over the last 90 days, insiders sold approximately $5.9 million in shares, including significant transactions by Director Noubar Afeyan and executive Shannon Thyme Klinger to cover tax obligations on vested equity awards.
📈 Brookline raised Q2 2026 Moderna EPS estimate to ($1.97).
💰 Moderna Q2 revenue hit $145M, beating the $102.93M consensus.
📉 Q2 loss of ($1.97) beat expected ($2.03) loss per share.
🏦 Institutional ownership is 75.33% with recent buys from MUFG and EverSource.
⚖️ Strong liquidity: current ratio 2.29, zero debt-to-equity, stock above 200-day average.
📈 Brookline Capital Markets raised Q2 2026 EPS estimate for Moderna to ($1.97) from ($1.98).
💰 Moderna reported Q2 revenue of $145.00 million, beating the consensus estimate of $102.93 million.
📉 The company posted a loss of ($1.97) per share for Q2 2026, beating the expected loss of ($2.03).
📊 Revenue grew by 2.1% year-over-year compared to the same quarter last year.
🏦 Institutional ownership stands at 75.33%, with recent purchases from MUFG Securities and EverSource Wealth Advisors.
💸 Insiders sold $5.928 million in stock over the last 90 days, primarily for tax withholding on equity awards.
📉 Q4 2026 EPS is forecasted at ($2.16) by Brookline Capital Markets.
🔬 Moderna's flagship product remains its mRNA-based COVID-19 vaccine with full approval in multiple jurisdictions.
📈 Stock price opened at $57.08, trading above the 200-day moving average of $52.87.
⚖️ The company maintains a strong liquidity position with a current ratio of 2.29 and zero debt-to-equity.
Bullish Signals
- Beat Q2 EPS estimates by $0.06.
- Revenue exceeded expectations at $145.00 million.
- Achieved 2.1% year-over-year revenue growth.
- Institutional investors increased positions by 148.3%.
- Stock trades above 200-day moving average.
Risk Factors
- Negative net margin of -141.43% and ROE of -28.30%.
- Insiders sold $5.9M; Director Afeyan reduced stake by 70.24%.
- Negative EPS of ($1.97) for Q2 2026.
Bullish Signals
- Moderna beat Q2 EPS estimates by $0.06, reporting ($1.97) versus the consensus of ($2.03).
- Revenue significantly exceeded expectations at $145.00 million compared to the estimated $102.93 million.
- The company achieved a 2.1% year-over-year revenue increase, demonstrating continued top-line growth.
- Brookline Capital Markets raised its Q2 EPS estimate and provided positive forward guidance for FY2027.
- Institutional investors like EverSource Wealth Advisors increased their positions by 148.3% in the second quarter.
- The stock trades above its 200-day moving average, indicating sustained investor interest.
Risk Factors
- Moderna reported a negative net margin of 141.43% and a negative return on equity of 28.30% for the quarter.
- Insiders sold $5.9 million in shares over the last 90 days, including Director Noubar Afeyan reducing his stake by 70.24%.
- The company continues to operate at a loss with a negative EPS of ($1.97) for Q2 2026.
Amundi reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 20.9% during the first quarter, selling 238,790 shares to retain a position valued at approximately $45.96 million. While Amundi decreased its stake, other institutional investors like MUFG Securities EMEA and Flagship Harbor Advisors established new positions, though their stakes remain relatively small compared to major funds. Overall, institutional ownership stands at 75.33% of the company's stock.
Analyst sentiment remains mixed with a consensus target price of $40.00, reflecting a 'Reduce' average rating. While Goldman Sachs and Piper Sandler raised their price objectives to $67.00 and $77.00 respectively, Wolfe Research reiterated an 'underperform' rating with a $25.00 target. Morgan Stanley adjusted its target to $39.00 with an 'equal weight' rating, highlighting the divergence in market expectations for the biotech firm.
Moderna reported quarterly earnings on July 31st, beating analyst estimates with revenue of $145.00 million compared to a consensus of $102.93 million. Despite the revenue beat, the company posted a loss of $1.97 per share versus an expected loss of $2.03, resulting in a negative net margin of 141.43%. Revenue grew by 2.1% year-over-year, but analysts expect continued losses with a projected annual earnings per share of -$6.41 for the current fiscal year.
Insider trading activity shows President Stephen Hoge sold 53,336 shares worth approximately $2.74 million under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 3.47%. Other insiders also executed sales to cover tax obligations, with corporate insider ownership currently at 10.80%. The stock trades at a market cap of $21.75 billion with a P/E ratio of -6.86, trading below its 50-day moving average of $59.37.
📉 Amundi sold shares, retaining a $45.96 million stake.
💰 Revenue hit $145M, beating estimates with a 2.1% rise.
📉 Reported loss of $1.97 per share, better than expected.
🎯 Analyst targets range from $25 to $77 with mixed ratings.
📉 Stock trades below key moving averages at $21.75B cap.
📉 Amundi lowered its Moderna position by 20.9% in Q1, selling 238,790 shares while retaining a stake worth $45.96 million.
📊 Institutional ownership remains high at 75.33%, with smaller firms like MUFG and Flagship Harbor establishing new positions.
💰 Moderna beat Q1 revenue estimates of $102.93 million with actual sales reaching $145.00 million, a 2.1% year-over-year increase.
📉 The company reported a loss of $1.97 per share, missing the consensus expectation of a slightly larger loss at -$2.03.
🎯 Analyst consensus target price is set at $40.00 with an average rating of 'Reduce' based on data from MarketBeat.
📈 Goldman Sachs raised its price objective to $67.00, while Piper Sandler increased theirs to $77.00 with an 'overweight' rating.
📉 Wolfe Research maintained an 'underperform' rating with a lower target price of $25.00 for the stock.
💼 President Stephen Hoge sold 53,336 shares worth $2.74 million under a pre-arranged trading plan on June 15th.
📉 Corporate insider ownership stands at 10.80% following recent sales by executives to cover tax withholding obligations.
📈 Moderna's stock trades at a market cap of $21.75 billion with a negative P/E ratio of -6.86 due to ongoing losses.
📉 The stock is currently trading below its 50-day moving average of $59.37 and 200-day moving average of $52.64.
🔬 Moderna's flagship mRNA-based COVID-19 vaccine remains the primary revenue driver for the biotechnology company.
Bullish Signals
- Revenue beat estimates at $145.00 million.
- Goldman Sachs raised target to $67.00.
- Piper Sandler upgraded to overweight with $77.00 target.
- Revenue grew 2.1% year over year.
Risk Factors
- Analyst price target is $25.00, below current levels.
- Quarterly loss of $1.97 per share continues.
- Consensus target is $40.00 with 'Reduce' rating.
- President sold 53,336 shares worth over $2.7 million.
Bullish Signals
- Moderna beat Q1 analyst revenue estimates, reporting $145.00 million in revenue against a consensus of $102.93 million.
- Goldman Sachs Group lifted its price objective on Moderna from $49.00 to $67.00 while maintaining a neutral rating.
- Piper Sandler increased its price target to $77.00 and upgraded the rating to 'overweight' in late June.
- Moderna achieved revenue growth of 2.1% compared to the same quarter in the prior year.
Risk Factors
- Wolfe Research reiterated an 'underperform' rating with a price target of $25.00, significantly below current levels.
- The company reported a loss of $1.97 per share for the quarter, indicating continued financial losses despite revenue growth.
- Analyst consensus targets the stock at $40.00 with an average rating of 'Reduce', suggesting limited near-term upside.
- President Stephen Hoge sold 53,336 shares worth over $2.7 million, reducing his personal stake by 3.47%.
The article identifies Moderna (NASDAQ:MRNA) as one of the top-performing S&P 500 stocks over the last decade, citing a 925.2% share price gain as of January 18. The company recently announced positive late-stage trial results for its RSV vaccine candidate, mRNA-1345, which demonstrated an 83.7% efficacy rate against lower respiratory tract disease in older adults.
Despite this recent success, Deutsche Bank analyst Emmanuel Papadakis raised Moderna's price target to $225 but maintained a loss estimate for the current fiscal year due to high R&D expenses. Hedge fund sentiment remains mixed, with 44 funds holding positions at the end of Q3 2022, led by Coatue Management which holds a significant stake worth approximately $674.7 million.
Baron Funds notes that Moderna has underperformed relative to other biotechnology sub-industries due to uncertainty regarding the commercialization of mRNA boosters as the market shifts from pandemic-driven government funding to a more commercial landscape.
📈 Moderna ranks in top 11 S&P 500 stocks with 925.2% decade gain.
💉 RSV vaccine shows 83.7% efficacy against lower respiratory disease in older adults.
📉 Deutsche Bank raised target to $225 but expects a loss this year.
⚠️ Baron Funds warns of biotech underperformance due to booster market uncertainty.
🏦 Coatue Management holds largest stake with 5.70 million shares valued at $674.7M.
📈 Moderna (NASDAQ:MRNA) is listed among the top 11 best-performing S&P 500 stocks over the last decade with a 925.2% share price gain as of January 18.
💉 The company announced late-stage trial results for its RSV vaccine candidate mRNA-1345, showing 83.7% efficacy against lower respiratory tract disease in older adults.
📉 Deutsche Bank analyst Emmanuel Papadakis raised the price target to $225 but expects Moderna to incur a loss this year due to planned research and development expenses.
🏦 Coatue Management is the largest hedge fund stakeholder with 5.70 million shares valued at $674.7 million as of Q3 2022.
⚠️ Baron Funds highlights underperformance in biotechnology due to uncertainty around booster markets and a shift from government-funded pandemic vaccines to commercial markets.
📊 Moderna is included in a broader list of top performers alongside NVIDIA, Tesla, Microsoft, T-Mobile, UnitedHealth, Lam Research, and ServiceNow.
Bullish Signals
- RSV vaccine candidate showed 83.7% efficacy against lower respiratory tract disease.
- Deutsche Bank raised price target to $225 with Buy rating.
- Moderna leads mRNA field for infectious, oncology, and autoimmune diseases.
Risk Factors
- Deutsche Bank expects Moderna loss due to R&D expenses.
- Baron Funds notes underperformance amid mRNA booster uncertainty.
- Stifel cites declining memory market fundamentals and investment contraction.
Bullish Signals
- Moderna's RSV vaccine candidate mRNA-1345 met core efficacy goals with an 83.7% efficacy rate against lower respiratory tract disease in older adults.
- Deutsche Bank analyst Emmanuel Papadakis raised the price target from $185 to $225 and maintained a 'Buy' rating despite trimming revenue estimates.
- Moderna is recognized as a leader in the emerging field of mRNA-based vaccines and therapeutics for infectious, immuno-oncology, rare, cardiovascular, and auto-immune diseases.
Risk Factors
- Deutsche Bank analyst expects Moderna to incur a loss this year due to planned research and development expenses.
- Baron Funds notes that Moderna has underperformed the biotechnology sub-industry due to uncertainty regarding the commercialization of mRNA boosters as the market shifts away from pandemic status.
- Stifel analyst Brian Chin cited declining fundamentals in the memory market and expects investments to contract sharply next year, though this specific comment targets Lam Research rather than Moderna directly.
Moderna Inc. (NASDAQ: MRNA) has seen its stock price double in 2026, rising over 170% year-to-date by early July and remaining up 90-100% by mid-July. This surge is driven by modest but significant financial improvements, including Q1 2026 revenue of $389 million, a 260% year-over-year increase, and a 26% reduction in adjusted cash costs. International markets now account for approximately 80% of top-line revenue, signaling a successful shift away from domestic post-pandemic demand.
Despite the stock rally, Wall Street sentiment remains mixed with consensus ratings largely at 'Hold' and analyst price targets ranging widely from $18 to $77. The company reported a GAAP net loss of $1.3 billion for Q1 2026, inflated by a $178 million Arbutus patent settlement and up to $1.3 billion in contingent legal costs related to ongoing litigation, including a new CureVac lawsuit. Institutional behavior reflects this caution, with Susquehanna cutting its stake by 96.6% and Moderna President Stephen Hoge executing a pre-planned stock sale.
The bull case relies on the oncology pipeline, which includes Phase 2b melanoma data showing relative strength and upcoming Phase 3 interim results later in 2026. A key near-term catalyst is the FDA's renewed review of the mRNA-1010 flu vaccine with a PDUFA date of August 5. However, long-term revenue from assets like a lupus CAR-T program will not materialize until at least 2028, leaving Moderna in a critical crossroads between pipeline validation and significant cash burn.
Analysts view Moderna as a high-risk, catalyst-driven company rather than a core compounder, with the wide spread in price targets reflecting uncertainty about future commercialization. While some hedge funds have increased their holdings, the substantial institutional selling and pending litigation costs suggest that the stock's dramatic re-rating is based more on incremental updates than definitive evidence of long-term value creation.
📈 Stock rose 170% YTD to near $77 highs in 2026.
💰 Q1 revenue hit $389M with international sales at 80%.
⚖️ GAAP loss of $1.3B driven by legal settlements and costs.
📅 FDA PDUFA date for flu vaccine set for August 5, 2026.
⚠️ Analysts view Moderna as high-risk with wide price targets.
📈 Moderna stock has risen over 170% year-to-date in 2026, reaching highs near $77 according to Piper Sandler.
💰 Q1 2026 revenue reached $389 million, up 260% year-over-year, with international markets contributing 80% of top-line sales.
📉 GAAP net loss for the quarter was $1.3 billion, heavily impacted by a $178 million Arbutus settlement and $1.3 billion in contingent legal costs.
⚖️ The company faces ongoing litigation including a new CureVac lawsuit with potential costs up to $1.3 billion.
🔬 Oncology pipeline shows promise with Phase 2b melanoma data read as relatively well at ASCO in June.
📅 FDA PDUFA date for the mRNA-1010 flu vaccine is set for August 5, 2026, providing a tangible near-term catalyst.
📊 Analyst consensus ratings remain largely 'Hold' with price targets ranging widely from $18 to $77.
🏦 Susquehanna Financial Group aggressively cut its Moderna stake by 96.6% in Q1 2026, dumping roughly 1.56 million shares.
💼 Moderna President Stephen Hoge sold $3.6 million in shares on July 15 via a pre-planned 10b5-1 transaction.
🚀 Long-term revenue from assets like the lupus CAR-T program will not begin until at least 2028.
⚠️ Analysts characterize Moderna as a high-risk, catalyst-driven company rather than a core long-term compounder.
Bullish Signals
- Stock doubled in 2026 with 170% YTD rise by early July.
- Q1 2026 revenue surged to $389 million, a 260% increase.
- Net product sales jumped 309% to $352 million in Q1.
- Adjusted cash costs fell 26% year-over-year showing improved discipline.
- International markets now represent approximately 80% of total revenue.
- PDUFA date for mRNA-1010 flu vaccine set for August 5, 2026.
Risk Factors
- Q1 2026 GAAP net loss reached $1.3 billion.
- $178 million charge for Arbutus patent settlement.
- Up to $1.3 billion in contingent legal costs.
- Susquehanna Financial Group cut holdings by 96.6%.
- Analyst price targets range widely from $18 to $77.
Bullish Signals
- Moderna stock has doubled in 2026 with a year-to-date rise of over 170% by early July.
- Q1 2026 revenue surged to $389 million, representing a 260% increase from the prior year.
- Net product sales increased by 309% to $352 million in Q1 2026.
- The company achieved a 26% year-over-year reduction in adjusted cash costs, demonstrating improved operational discipline.
- International markets now account for approximately 80% of total revenue, indicating a successful geographic diversification.
- Phase 2b adjuvant melanoma follow-up results reported at ASCO were read as relatively well.
- Piper Sandler raised its price target to $77 from $69, citing the company's Science Day event and data updates.
- The FDA has renewed its review of the mRNA-1010 flu vaccine with a PDUFA date of August 5, 2026.
Risk Factors
- GAAP net loss for Q1 2026 was $1.3 billion, significantly inflated by non-operating items.
- The company incurred a $178 million charge related to the Arbutus patent settlement.
- Moderna faces up to $1.3 billion in contingent legal costs associated with ongoing litigation, including the CureVac lawsuit.
- Susquehanna Financial Group reduced its Moderna holding by 96.6% in Q1 2026, selling approximately 1.56 million shares.
- Moderna President Stephen Hoge executed a pre-planned stock sale of $3.6 million on July 15 at a price far above recent trading levels.
- Analyst consensus ratings remain largely 'Hold' with a wide spread in price targets ranging from $18 to $77.
Moderna (MRNA) is approaching its Q2 2026 earnings report due on July 31, following a streak of five consecutive quarterly beats. The company recently reported Q1 revenue of $389 million, significantly beating the consensus estimate of $236.36 million and showing year-over-year growth. Market sentiment is highly bullish ahead of the release, with traders pricing an 84% probability of another beat and a put/call ratio of 0.12 indicating strong call option interest.
The stock faces two major catalysts: a potential FDA approval for its mRNA-1010 respiratory vaccine on August 5, which would add a fifth commercial product to its portfolio, and positive Phase 3 data for its intismeran melanoma candidate later in the year. Management has reaffirmed revenue growth guidance of up to 10% based on a $1.94 billion 2025 base and expects to maintain a cash position between $4.5 billion and $5.0 billion by year-end 2026.
Despite posting large GAAP losses, the company's underlying business appears robust given the recent earnings performance and upcoming product milestones. The approval of mRNA-1010 is critical for rebuilding its respiratory franchise ahead of the 2026 to 2027 flu season, while the melanoma data could further diversify its pipeline beyond infectious diseases.
📈 Q1 2026 revenue hit $389M, beating estimates by 64.58%.
🔮 Traders expect an 84% chance of another earnings beat.
💉 FDA approval for mRNA-1010 could make Moderna a five-product company.
🧬 Intismeran shows 49% lower recurrence risk vs KEYTRUDA alone.
💰 Company projects $4.5-$5.0B cash by end of 2026.
📈 Moderna reported Q1 2026 revenue of $389M, a 64.58% beat against consensus and 263.6% YoY growth.
🔮 Traders price an 84% probability of another earnings beat with a put/call ratio of 0.12 ahead of the July 31 report.
💉 An FDA approval for mRNA-1010 on August 5 would make Moderna a five-product company, revitalizing its respiratory franchise.
🧬 Phase 3 data for intismeran melanoma is due later this year, showing a 49% reduction in recurrence or death risk versus KEYTRUDA alone.
💰 Management expects to finish 2026 with $4.5-$5.0B in cash and investments despite large GAAP losses.
📈 The stock has gained 83% in 2026, extending a rally driven by earnings beats and pipeline progress.
🏥 Moderna is developing intismeran alongside Merck's KEYTRUDA to treat melanoma with reduced recurrence risk.
Bullish Signals
- Q1 revenue beat $389M vs $236.36M consensus.
- Stock rallied 83% in 2026, outperforming sector.
- FDA approval for mRNA-1010 adds fifth product.
- Guidance up to 10% growth on $1.94B base.
- Melanoma candidate shows 49% risk reduction.
Risk Factors
- GAAP losses persist despite non-operating factors like $878M litigation settlement.
- Relies on Aug 5 FDA approval for mRNA-1010 to recover.
Bullish Signals
- Moderna delivered a massive Q1 revenue beat of $389M versus the $236.36M consensus, extending a streak of five consecutive quarterly beats.
- The stock has rallied 83% in 2026, significantly outperforming the broader biotech sector which is up only 0.4% year-to-date.
- A potential August 5 FDA approval for mRNA-1010 would add a fifth commercial product to Moderna's portfolio, strengthening its respiratory franchise.
- Management reaffirmed revenue growth guidance of up to 10% on a $1.94B 2025 base and expects strong cash reserves of $4.5-$5.0B by year-end 2026.
- Phase 3 data for the intismeran melanoma candidate is expected later this year, showing a 49% reduction in recurrence or death risk compared to KEYTRUDA alone.
Risk Factors
- Moderna continues to post large GAAP losses, although management attributes some of this to non-operating factors like an $878 million litigation settlement included in Q1.
- The company relies heavily on upcoming regulatory decisions, specifically the August 5 FDA approval for mRNA-1010, to validate its respiratory franchise recovery.
Moderna (NASDAQ: MRNA) is scheduled to announce its Q2 2026 earnings results before the market opens on Friday, July 31st, with a conference call set for 8:00 AM ET. Analysts currently anticipate a loss of $2.00 per share and revenue of approximately $103 million for the quarter.
The company previously reported Q1 2026 results on May 1st, delivering a significant surprise with revenue of $389 million against consensus estimates of $236.37 million, representing a 260.2% year-over-year increase. Despite the strong top-line growth, the firm posted an earnings per share (EPS) loss of $3.40, missing analyst expectations of a smaller loss of $3.02.
Moderna's stock recently opened at $57.02, trading above its 200-day moving average but below its 50-day average. The company maintains a strong balance sheet with a market capitalization of $22.62 billion and minimal debt, though it carries a negative P/E ratio due to recent losses. Institutional ownership stands at 75.33%.
Wall Street sentiment remains mixed ahead of the upcoming report. Major brokerages have issued varied outlooks, with Morgan Stanley raising its price target to $39.00 and Royal Bank of Canada increasing its target to $45.00, while Bank of America maintains an underperform rating with a $38.00 target. The average analyst target price is currently set at $40.00.
📅 Moderna releases Q2 2026 earnings Friday, July 31st before market open.
💰 Analysts expect $103M revenue and $2.00 quarterly loss for Q2 2026.
🚀 Q1 2026 revenue surged 260.2% to $389M, beating consensus estimates.
📉 Q1 EPS was a $3.40 loss, missing the $3.02 analyst estimate.
🎯 Average analyst target price is $40.00 with a 'Reduce' consensus rating.
📅 Moderna will release Q2 2026 earnings on Friday, July 31st, before the market opens.
💰 Analysts expect a quarterly loss of $2.00 per share and revenue of $103 million.
🚀 Q1 2026 revenue surged 260.2% year-over-year to $389 million, significantly beating the $236.37 million consensus.
📉 Q1 EPS was a loss of $3.40, missing analyst estimates of a $3.02 loss.
📈 Stock opened at $57.02, trading between its 50-day ($58.42) and 200-day ($51.75) moving averages.
💵 Market capitalization is valued at $22.62 billion with a debt-to-equity ratio of only 0.08.
🏦 Institutional ownership is high at 75.33%, led by significant holdings from Brown Brothers Harriman and Zions Bancorporation.
📊 Morgan Stanley raised its price target to $39.00 with an equal weight rating.
🔻 Bank of America maintains an underperform rating with a price objective of $38.00.
🎯 The average analyst target price is $40.00, reflecting a 'Reduce' consensus rating.
Bullish Signals
- Q1 2026 revenue hit $389M, up 260.2% year-over-year.
- Strong liquidity with quick ratio of 2.35 and current ratio of 2.41.
- Minimal debt with a low debt-to-equity ratio of 0.08.
- Morgan Stanley raised price target to $39.00.
- Royal Bank of Canada set price objective at $45.00.
Risk Factors
- Q1 2026 EPS loss of $3.40 missed expectations.
- Bank of America underperform rating with $38.00 target.
- Weiss Ratings sell and Jefferies neutral sentiment.
- $40.00 average target implies potential downside risk.
Bullish Signals
- Moderna reported Q1 2026 revenue of $389 million, which was 260.2% higher than the same quarter last year and significantly exceeded analyst estimates.
- The company maintains a robust balance sheet with a quick ratio of 2.35 and a current ratio of 2.41, indicating strong liquidity.
- Debt levels are minimal with a debt-to-equity ratio of just 0.08, providing financial flexibility for R&D or strategic initiatives.
- Morgan Stanley increased its price target from $33.00 to $39.00, signaling confidence in the company's long-term prospects.
- Royal Bank of Canada raised its price objective to $45.00, suggesting a more bullish outlook than the broader analyst consensus.
Risk Factors
- Moderna reported a Q1 2026 EPS loss of $3.40, which missed analyst expectations of a smaller loss of $3.02.
- Bank of America maintains an underperform rating with a price objective of $38.00, which is below the current stock price.
- Weiss Ratings reaffirmed a sell rating, while Jefferies Financial Group holds a neutral stance, contributing to a mixed analyst sentiment.
- The average analyst target price of $40.00 implies a potential downside from the recent trading levels if consensus estimates hold.
Fifth Third Bancorp significantly increased its stake in Moderna, Inc. (MRNA) by 157.5% in the first quarter, purchasing an additional 36,912 shares to hold a total position of 60,341 shares valued at $3.065 million. Other institutional investors like MUFG Securities EMEA and Flagship Harbor Advisors also established new positions, while Cromwell Holdings and EverSource Wealth Advisors increased their holdings by nearly 40% and 148%, respectively. Institutional ownership of the stock stands at 75.33%.
Analyst sentiment remains mixed with a consensus rating of 'Reduce' and a target price of $38.80, though recent reports show diverging views. Goldman Sachs raised its price target to $49.00 with a neutral rating, while Piper Sandler lifted its objective to $77.00 with an overweight rating. Conversely, Jefferies maintained a hold, and Barclays adjusted its target to $48.00 with an equal weight rating. Morgan Stanley also raised its target to $39.00.
Insider trading activity reveals significant selling pressure as executives reduced their positions. Director Abbas Hussain sold 5,682 shares for approximately $265,000, and insider Shannon Thyme Klinger sold 3,471 shares for about $173,550 to cover tax obligations on vested equity. Collectively, insiders sold over 125,000 shares worth roughly $6.19 million in the last three months.
Moderna reported first-quarter earnings of ($3.40) per share, missing analyst estimates of ($3.02), though revenue surged to $389 million, beating expectations of $236.37 million and representing a 260% year-over-year increase. The stock currently trades at $59.49 with a market cap of $23.61 billion, trading above its 50-day moving average but below its one-year high of $85.60.
📈 Fifth Third Bancorp added 60,341 MRNA shares worth $3.065 million in Q1.
🏦 Multiple institutions established or increased new positions in the stock.
📉 Analyst consensus is 'Reduce' at $38.80 despite Goldman Sachs raising target to $49.00.
💰 Insiders sold 125,088 shares worth $6.19 million over the last three months.
📊 Q1 revenue surged 260.2% to $389 million, beating estimates significantly.
📈 Fifth Third Bancorp increased its MRNA stake by 157.5% in Q1, adding 36,912 shares to a total holding of 60,341 shares valued at $3.065 million.
🏦 Other institutions including MUFG Securities EMEA, Flagship Harbor Advisors, Cromwell Holdings, and EverSource Wealth Advisors established or increased new positions in the stock.
📉 Analyst consensus rating is 'Reduce' with a target price of $38.80, despite Goldman Sachs raising its target to $49.00 and Piper Sandler lifting its objective to $77.00.
💰 Insider selling activity was significant in the last three months, with executives offloading 125,088 shares worth approximately $6.19 million.
📊 Q1 revenue jumped 260.2% year-over-year to $389 million, significantly beating the consensus estimate of $236.37 million.
💸 The company reported a net loss of $3.40 per share for the quarter, missing analyst estimates by $0.38.
📈 Stock price opened at $59.49, trading above its 50-day moving average of $58.00 and 200-day moving average of $51.15.
🏢 Institutional investors own 75.33% of the outstanding shares, while corporate insiders hold 10.80%.
Bullish Signals
- Revenue surged 260.2% to $389 million.
- Beat estimates by $152.63 million.
- Goldman Sachs raised target to $49.
- Piper Sandler lifted target to $77.
- Morgan Stanley increased target to $39.
- Barclays raised target to $48.
- Fifth Third Bancorp grew position 157.5%.
- Trading above 50-day ($58) and 200-day ($51.15) averages.
Risk Factors
- Loss of $3.40 per share, missing estimates by $0.38.
- Consensus target price of $38.80 is below current trading price.
- Ten analysts Hold while five issued Sell ratings.
- Insiders sold 125,088 shares worth $6.19 million recently.
- Director Abbas Hussain sold 5,682 shares, a 32.01% drop.
Bullish Signals
- Moderna reported first-quarter revenue of $389 million, which was a 260.2% increase compared to the same quarter last year.
- The company beat analyst consensus estimates for revenue by $152.63 million, reporting $389 million against an expected $236.37 million.
- Goldman Sachs raised its price target on MRNA from $43.00 to $49.00 in a recent research report.
- Piper Sandler lifted its price objective from $69.00 to $77.00 and assigned an 'overweight' rating to the stock.
- Morgan Stanley increased its target price on MRNA from $33.00 to $39.00 in a report issued on July 8th.
- Barclays raised its target price on Moderna from $25.00 to $48.00, indicating a higher valuation expectation.
- Fifth Third Bancorp significantly grew its position by 157.5% in the first quarter, signaling strong institutional confidence.
- The stock is trading above both its 50-day moving average ($58.00) and its 200-day moving average ($51.15).
Risk Factors
- Moderna reported a loss of $3.40 per share for the quarter, missing analyst consensus estimates by $0.38.
- Analyst consensus rating is 'Reduce' with a consensus target price of $38.80, which is below the current trading price.
- Ten analysts have issued a Hold rating while five have given a Sell rating to the company's stock.
- Insiders sold 125,088 shares worth approximately $6.19 million in the last three months, indicating reduced personal conviction.
- Director Abbas Hussain sold 5,682 shares representing a 32.01% decrease in his ownership stake.
- The stock has a PE ratio of -7.30, reflecting its current unprofitable status.
D.A. Davidson & CO. reduced its position in Moderna, Inc. (NASDAQ: MRNA) by 33.7% during the first quarter, selling 28,170 shares to hold a remaining stake of 55,397 shares valued at $2.814 million. This filing highlights a mixed institutional landscape where other major funds like Capital World Investors and Norges Bank established new stakes in the fourth quarter, while Dimensional Fund Advisors significantly increased its holdings by over 123%.
Moderna's stock currently trades with a market capitalization of $24.53 billion and a negative P/E ratio of -7.59, reflecting its biotechnology sector status. The company maintains strong liquidity metrics with a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Recent insider activity includes President Stephen Hoge selling approximately $2.74 million in shares and Director Abbas Hussain reducing his position by over 32%, though total corporate insider ownership remains at 10.80%.
Analyst sentiment regarding MRNA is currently mixed, with a consensus target price of $38.27 from MarketBeat data. While Royal Bank of Canada and Piper Sandler raised their price targets to $45 and $77 respectively with positive or overweight ratings, Goldman Sachs and Bank of America maintain neutral to underperform ratings. The average analyst rating is 'Reduce', indicating a cautious outlook despite the company's established mRNA platform for vaccines and therapeutics.
📉 D.A. Davidson cut holdings by 33.7% to $2.814 million value.
📈 Capital World and Norges Bank added $378M and $79.7M stakes.
💼 President Hoge sold 53,336 shares for $2.74 million in June.
⚖️ Insider sales totalled 125,088 shares worth $6.19 million recently.
🎯 Consensus target is $38.27 with an average 'Reduce' rating.
📉 D.A. Davidson & CO. decreased its Moderna holdings by 33.7% in Q1, selling 28,170 shares to retain a position worth $2.814 million.
📈 Capital World Investors and Norges Bank established new stakes in the fourth quarter valued at approximately $378 million and $79.7 million respectively.
📊 Moderna trades with a market cap of $24.53 billion, a quick ratio of 2.35, and a negative P/E ratio of -7.59.
💼 President Stephen Hoge sold 53,336 shares for $2.74 million under a pre-arranged Rule 10b5-1 trading plan on June 15th.
📉 Director Abbas Hussain reduced his ownership by 32.01% following the sale of 5,682 shares valued at $264,951.
🏦 Corporate insiders have collectively sold 125,088 shares worth $6.19 million over the last ninety days.
📊 Royal Bank of Canada raised its price target to $45.00 with a 'sector perform' rating on July 7th.
📈 Piper Sandler increased its objective to $77.00 and assigned an 'overweight' rating in late June.
⚖️ Goldman Sachs lifted its target price to $49.00 but maintains a 'neutral' stance as of early May.
📉 Bank of America raised its target to $38.00 while assigning an 'underperform' rating on July 7th.
🎯 The consensus analyst target price stands at $38.27 with an average rating of 'Reduce' across twelve analysts.
💊 Moderna specializes in mRNA therapeutics and vaccines, leveraging synthetic mRNA to produce proteins for disease prevention.
Bullish Signals
- Capital World Investors added $378.3M stake in Q4.
- Norges Bank bought $79.7M position in Q4.
- Invesco increased Moderna stake by 15.7% to $212.2M.
- Dimensional Fund Advisors raised holdings by 123.2% in Q4.
- Royal Bank of Canada set price target at $45.00.
- Piper Sandler raised objective to $77.00 with overweight rating.
- Moderna liquidity strong with quick ratio of 2.35.
Risk Factors
- DA Davidson cut holdings by 33.7% in Q1.
- Consensus target $38.27 is below recent price $61.82.
- Average analyst rating is 'Reduce'.
- President Hoge sold 53,336 shares (3.47% decrease).
- Insiders sold 125,088 shares worth $6.19 million.
Bullish Signals
- Capital World Investors initiated a new stake worth approximately $378.3 million in the fourth quarter.
- Norges Bank purchased a new position valued at roughly $79.7 million during the fourth quarter.
- Invesco Ltd. increased its Moderna stake by 15.7% in the third quarter, now holding shares worth $212.2 million.
- Dimensional Fund Advisors LP raised its holdings by 123.2% in the fourth quarter, adding nearly 987,000 shares.
- Royal Bank of Canada upgraded its price target to $45.00 with a 'sector perform' rating.
- Piper Sandler increased its price objective to $77.00 and assigned an 'overweight' rating.
- Moderna maintains strong liquidity with a quick ratio of 2.35 and a current ratio of 2.41.
Risk Factors
- D.A. Davidson & CO. significantly reduced its holdings by 33.7% in the first quarter.
- The consensus analyst target price is $38.27, which is below the recent trading price of $61.82.
- The average analyst rating is 'Reduce' based on data from MarketBeat.com.
- President Stephen Hoge sold 53,336 shares representing a 3.47% decrease in his personal position.
- Director Abbas Hussain reduced his ownership by 32.01% following the sale of 5,682 shares.
- Corporate insiders have sold a total of 125,088 shares valued at $6.19 million in the last ninety days.
- Goldman Sachs maintains a 'neutral' rating despite raising its price target to $49.00.
- Bank of America assigned an 'underperform' rating even after lifting its price objective to $38.00.
Moderna, Inc. (MRNA) is ranked 9th on a list of worst-performing stocks to buy on the dip, according to an analysis published on October 1, 2024. The article contextualizes this ranking within a broader market environment characterized by volatility in late 2024, driven by Federal Reserve rate cut expectations and a rotation away from technology sectors toward real estate and utilities.
The company faces significant near-term headwinds, including declining COVID-19 vaccination rates and delayed revenue ramp-up for its RSV vaccine. Consequently, Moderna plans to reduce its Research and Development budget by approximately 20% over the next three years, discontinuing five programs to cut $1.1 billion from its annual spend by 2027. The company also provides limited sales guidance for 2025 and targets a return to profitability in 2028.
Despite these challenges, Wall Street analysts remain optimistic about Moderna's long-term prospects, citing positive Phase III results for a flu/COVID-19 combo vaccine and recent strategic alliances with BARDA and Mitsubishi Tanabe Pharma. The company expects Q3 2024 sales to increase by 40%–50%, aims to end the year with roughly $9 billion in cash, and has an average analyst target price of $104.53.
📉 Moderna ranks 9th on worst-performing stocks list as of Sept 27.
💰 Company cuts R&D budget by ~20%, reducing annual spend to $1.1B by 2027.
🔬 Three new products, including next-gen COVID and adult RSV vaccines, expected for approval this year.
📈 Q3 2024 sales projected to rise 40%–50% compared to the prior year.
💵 Moderna targets ~$9 billion cash reserves by end of 2024.
📉 Moderna ranks 9th on a list of worst-performing stocks to buy on the dip as of September 27.
📅 The article was published on October 1, 2024, amidst market volatility driven by Federal Reserve rate cut expectations.
💰 Moderna plans to reduce its R&D budget by ~20% over three years, cutting $1.1 billion from annual spend by 2027.
📉 The company faces headwinds from declining COVID-19 vaccination rates and delayed RSV vaccine revenue ramp-up.
🔬 Moderna expects to file for approval of three new products this year, including a next-gen COVID vaccine and an RSV vaccine for adults aged 18–59.
🤝 Recent strategic alliances were announced with BARDA and Mitsubishi Tanabe Pharma to aid product roll-outs.
📈 The company expects Q3 2024 sales to increase by 40%–50% compared to the prior year.
💵 Moderna targets ending 2024 with approximately $9 billion in cash reserves.
🎯 Wall Street analysts have set an average target price of $104.53 for MRNA shares.
⏳ The company plans to achieve operational break-even by 2028 despite providing only light guidance for 2025.
Bullish Signals
- Q3 2024 sales expected up 40%–50%.
- EMA gave positive opinion on RSV vaccine mRESVIA.
- Phase III flu/COVID combo vaccine results positive.
- Alliances with BARDA and Mitsubishi aid roll-outs.
- $9 billion cash by end of 2024.
Risk Factors
- R&D budget cuts ~20% due to low sales projections.
- Discontinuing programs slashes $1.1B from annual R&D budget.
- Declining vaccination rates create short-term revenue headwinds.
- Light 2025 guidance reflects near-term demand uncertainty.
- Targets break-even by 2028 indicating profitability challenges.
Bullish Signals
- Moderna expects Q3 2024 sales to increase by 40%–50%, indicating strong near-term revenue performance.
- The company received a positive opinion from the European Medicine Agency regarding its RSV vaccine, mRESVIA.
- Moderna achieved positive Phase III results for its flu and COVID-19 combo vaccine, validating its pipeline progress.
- Strategic alliances with BARDA and Mitsubishi Tanabe Pharma are expected to aid future product roll-outs and commercialization.
- The company plans to end 2024 with approximately $9 billion in cash, providing a strong balance sheet for operations.
Risk Factors
- Moderna plans to reduce its R&D budget by ~20% over the next three years due to low sales projections.
- The company will discontinue five research and development programs to slash $1.1 billion from its annual R&D budget by 2027.
- COVID-19 vaccination rates are likely to continue declining, creating short-term revenue headwinds.
- Moderna provides only light sales guidance for 2025, reflecting uncertainty in near-term demand.
- The company targets a return to break-even operations by 2028, indicating current profitability challenges.
Apollon Wealth Management LLC purchased 6,842 shares of Moderna (MRNA) in the first quarter, valued at approximately $348,000. Other institutional investors including MUFG Securities EMEA plc and Flagship Harbor Advisors LLC also added new positions worth roughly $28,000 and $31,000 respectively in the second and fourth quarters. Smaller funds like Ameriflex Group Inc. and Cromwell Holdings LLC significantly increased their holdings by over 3,700% and 39.7% respectively, though their total share counts remain relatively low compared to major institutions.
Insider trading activity saw significant sales from company leadership. Director Abbas Hussain sold 5,682 shares for approximately $264,951 in a pre-arranged Rule 10b5-1 plan on May 1st. President Stephen Hoge executed a larger sale of 53,336 shares worth about $2.74 million on June 15th under a similar trading plan. Collectively, insiders sold over 125,000 shares valued at more than $6.19 million during the last quarter, leaving them with 10.80% ownership of the company.
Moderna reported its latest earnings on May 1st, posting revenue of $389 million which beat analyst estimates of $236.37 million by a wide margin, representing a 260.2% year-over-year increase. However, the company reported an EPS loss of $3.40 per share, missing the consensus estimate of a smaller loss of $3.02. The stock currently trades at a market cap of $32.46 billion with a price-to-earnings ratio of -10.04, reflecting its unprofitable status despite strong revenue growth.
The article provides detailed financial metrics including a current ratio of 2.41 and a debt-to-equity ratio of 0.08, indicating a strong balance sheet with minimal debt. Analysts forecast an EPS of -6.51 for the current year. Moderna specializes in mRNA therapeutics and vaccines, with its flagship product being the COVID-19 vaccine which received full approval in multiple jurisdictions. The stock has seen significant volatility, trading between a one-year low of $22.28 and a high of $85.60.
📈 Apollon Wealth acquired 6,842 shares valued at $348,000 in Q1.
📉 President Hoge sold 53,336 shares worth $2.74 million on June 15.
💰 Moderna revenue hit $389M, beating estimates of $236.37M.
🚀 Revenue surged 260.2% year-over-year showing strong top-line growth.
🏦 Institutional investors own 75.33% of Moderna's outstanding stock.
📈 Apollon Wealth Management LLC acquired a new stake of 6,842 shares valued at approximately $348,000 in the first quarter.
📉 President Stephen Hoge sold 53,336 shares worth roughly $2.74 million on June 15th under a pre-arranged trading plan.
💰 Moderna reported revenue of $389 million for the quarter, significantly beating the consensus estimate of $236.37 million.
📊 The company posted an EPS loss of $3.40 per share, missing analyst expectations of a smaller loss of $3.02.
🚀 Revenue increased by 260.2% compared to the same quarter last year, demonstrating strong top-line growth.
🏦 Institutional investors own 75.33% of the company's outstanding stock as of the latest filings.
📉 Insiders collectively sold over 125,000 shares valued at more than $6.19 million during the last quarter.
💸 The stock currently trades with a market capitalization of $32.46 billion and a negative P/E ratio of -10.04.
🛡️ Moderna maintains a robust balance sheet with a current ratio of 2.41 and a debt-to-equity ratio of 0.08.
🔬 The company specializes in mRNA therapeutics, leveraging synthetic mRNA to produce proteins for disease prevention and treatment.
Bullish Signals
- Revenue hit $389M, beating estimates.
- Revenue surged 260.2% year-over-year.
- Strong liquidity with current ratio of 2.41.
- Minimal debt with D/E ratio of 0.08.
- Institutional ownership stands at 75.33%.
Risk Factors
- EPS loss of $3.40 missed consensus estimate of -$3.02.
- Analysts forecast negative EPS of -6.51 for current year.
- President Hoge sold 53,336 shares worth $2.74 million.
- Collective insider sales exceeded 125,000 shares valued at $6.19 million.
Bullish Signals
- Moderna reported revenue of $389 million, which significantly exceeded the consensus estimate of $236.37 million.
- Revenue grew by 260.2% year-over-year compared to the same quarter last year.
- The company maintains a strong liquidity position with a current ratio of 2.41 and a quick ratio of 2.35.
- Debt levels are minimal with a debt-to-equity ratio of only 0.08.
- Institutional ownership remains high at 75.33%, indicating continued confidence from major investors.
Risk Factors
- The company reported an EPS loss of $3.40 per share, missing the consensus estimate of a smaller loss of $3.02.
- Analysts forecast a negative EPS of -6.51 for the current year, indicating continued unprofitability.
- Significant insider selling occurred with President Stephen Hoge offloading 53,336 shares worth approximately $2.74 million.
- Collective insider sales exceeded 125,000 shares valued at over $6.19 million during the last quarter.
Moderna (MRNA) shares surged to a 52-week peak of $81.42 on July 6, marking a 169% annual gain and pushing the market cap to approximately $32.2 billion. This rally was driven by renewed enthusiasm for mRNA technology, including FDA advisory panel endorsement for its seasonal influenza vaccine (mRNA-1010) for adults over 50, and progress on its in vivo CAR-T initiative targeting autoimmune conditions.
Despite the stock price momentum, Wall Street analysts maintain a cautious stance with an average 'Reduce' rating and a consensus price target of $37.13, significantly below current trading levels. Goldman Sachs raised its projection to $49 while maintaining a neutral stance, whereas Bank of America and Barclays adjusted targets upward but kept underperform or equal weight ratings respectively.
Financial performance in Q1 showed mixed results with revenue surging 260% year-over-year to $389 million, beating estimates, though EPS missed at -$3.40 versus a forecast of -$3.02. While institutional investors like Louisiana State Employees Retirement System expanded holdings, corporate insiders collectively sold over 125,000 shares worth more than $6.1 million in the last 90 days.
📈 Stock hit $81.42 high with 169% annual return.
💰 Q1 revenue surged 260% to $389 million.
🏥 FDA panel unanimously endorsed flu vaccine for seniors.
🧬 mRNA-6007 CAR-T therapy advanced into preliminary development.
📉 Analysts maintain 'Reduce' rating with $37.13 price target.
📈 Moderna stock hit a 52-week high of $81.42 on July 6, representing a 169% total return over the past year.
🏥 The FDA advisory panel unanimously endorsed Moderna's experimental seasonal flu vaccine (mRNA-1010) for individuals aged 50 and older.
🧬 mRNA-6007, an in vivo CAR-T therapy for autoimmune diseases like systemic lupus erythematosus, advanced into preliminary development.
💰 Q1 revenue jumped 260% year-over-year to $389 million, significantly exceeding the analyst estimate of $236.37 million.
📉 Analyst consensus remains 'Reduce' with a mean price target of $37.13, less than half of the current trading price.
🏦 Goldman Sachs raised its price target to $49 while maintaining a neutral rating on the stock.
📉 Corporate insiders sold 125,088 shares totaling over $6.1 million during the previous 90-day period.
🏛️ Board member Noubar Afeyan reduced his position by 70.24% by selling 9,263 shares on May 21.
📊 Institutional ownership stands at 75.33%, with Louisiana State Employees Retirement System establishing a new position of 17,700 shares.
📉 Moderna reported Q1 earnings per share of -$3.40, missing the consensus forecast of -$3.02.
Bullish Signals
- Stock hit 52-week peak of $81.42 with 169% annual gain.
- Q1 revenue surged 260.2% to $389 million, beating estimates.
- FDA panel unanimously endorsed seasonal flu vaccine for ages 50+.
- mRNA-6007 CAR-T initiative advancing into preliminary autoimmune development.
- Institutional investors accumulating shares; LSE added 17,700 shares.
Risk Factors
- Analysts target $37.13, under 50% of current price.
- Insiders sold 125,088 shares worth over $6.1 million.
- Q1 EPS hit -$3.40, missing the -$3.02 forecast.
- Equity ranks as most overextended per InvestingPro analytics.
Bullish Signals
- Moderna stock reached a fresh 52-week peak of $81.42, delivering a remarkable 169% annual increase and a 124% climb over six months.
- Q1 revenue surged 260.2% year-over-year to $389 million, significantly beating the analyst estimate of $236.37 million.
- The FDA advisory panel delivered a unanimous endorsement for Moderna's experimental seasonal influenza vaccine (mRNA-1010) for the 50-and-over demographic.
- Moderna disclosed that its mRNA-6007 in vivo CAR-T initiative is advancing into preliminary development targeting autoimmune conditions like systemic lupus erythematosus.
- Institutional investors are accumulating shares, with Louisiana State Employees Retirement System establishing a fresh position of 17,700 shares valued at approximately $899,000.
Risk Factors
- Wall Street analysts hold an average 'Reduce' stance with a consensus price objective of $37.13, representing less than 50% of current trading levels.
- Corporate insiders have offloaded 125,088 shares totaling more than $6.1 million over the previous 90 days, indicating potential lack of confidence at current valuations.
- Q1 earnings per share registered at -$3.40, falling short of the consensus forecast of -$3.02 despite strong revenue growth.
- InvestingPro analytics position the equity among the platform's most overextended securities when measured against its Fair Value assessment.
Moderna (MRNA) shares surged 14% to $68 in Friday afternoon trading, reaching a new 52-week high of $69.29. The rally significantly outpaced peers Merck (MRK), which rose 2%, and Pfizer (PFE), which gained 2%. Analysts attribute the move to momentum from a recent FDA advisory committee vote endorsing Moderna's flu vaccine, mFlusiva, for adults 50 and older, alongside bullish pipeline messaging regarding oncology and autoimmune diseases.
Fundamentally, Moderna reported strong Q1 2026 revenue of $389 million, representing a 264% year-over-year increase that beat consensus estimates by 65%. The company reaffirmed guidance for up to 10% revenue growth in 2026. However, the stock trades at a forward P/E ratio of 23x on uncertain earnings, with a consensus analyst price target of $43.45, well below current levels. Insider transactions have recently tilted toward selling, suggesting investors should maintain modest position sizes given the stock's volatility.
Looking ahead, the next major catalyst is the August 5, 2026 FDA decision on mRNA-1010, which would mark Moderna's fifth approved product if cleared by the PDUFA date. Investors are also monitoring upcoming Phase 3 readouts for norovirus, intismeran in melanoma, and propionic acidemia. While the stock has gained 45% over the past month against Merck's 7% gain and Pfizer's decline, the sell-side consensus remains cautious with multiple Hold ratings.
📈 Moderna shares hit new 52-week high of $69.29.
💰 Q1 revenue surged 264% to $389 million, beating estimates.
🏥 FDA unanimously endorsed flu vaccine mFlusiva for adults 50+.
⏳ August 5, 2026 FDA decision on mRNA-1010 is key.
🎯 Company targets 2028 break-even while expanding oncology therapies.
📈 Moderna shares jumped 14% to $68, hitting a new 52-week high of $69.29 in Friday afternoon trading.
🏥 The FDA advisory committee unanimously endorsed Moderna's flu vaccine mFlusiva for adults 50 and older.
💰 Q1 2026 revenue reached $389 million, a 264% year-over-year increase that beat consensus by 65%.
📅 The company reaffirmed guidance for up to 10% revenue growth in 2026 in its latest 10-Q filing.
🎯 Moderna aims for a 2028 break-even goal while expanding into oncology and autoimmune disease therapies.
📉 Pfizer's Comirnaty revenue fell 59% to $232 million, highlighting reliance on non-COVID portfolios.
📊 Moderna stock is up 45% over the past month compared to Merck's 7% gain and Pfizer's 6% loss.
💸 The consensus analyst price target sits at $43.45, significantly below today's trading price of $68.
📉 Recent insider transactions show a net selling trend with 75 recent deals tilting toward sales.
⏳ The next major catalyst is the August 5, 2026 FDA decision on mRNA-1010 approval.
🔬 Upcoming Phase 3 readouts for norovirus, intismeran in melanoma, and propionic acidemia are being watched.
🏦 Jefferies raised its price target to $53 while maintaining a Hold rating on the stock.
Bullish Signals
- Shares surged 14% to new 52-week high of $69.29.
- FDA unanimously endorsed flu vaccine mFlusiva for adults 50+.
- Q1 2026 revenue jumped 264% YoY to $389 million.
- Company reaffirmed up to 10% revenue growth guidance for 2026.
- Stock gained 45% this month while peers lagged behind.
Risk Factors
- Analyst target $43.45 is well below current price of $68.
- Stock trades at forward P/E of 23x on uncertain earnings.
- Recent insider net selling trend with 75 recent sales deals.
- Leerink target near $24 and Morgan Stanley near $33.
- Pfizer revenue fell 59% to $232 million in Q1 2026.
- Consensus cautious with 16 Hold ratings against Buys and Sells.
Bullish Signals
- Moderna shares surged 14% to hit a new 52-week high of $69.29, significantly outperforming peers Merck and Pfizer.
- The FDA advisory committee unanimously endorsed Moderna's flu vaccine mFlusiva for adults 50 and older.
- Q1 2026 revenue jumped 264% year-over-year to $389 million, beating consensus estimates by 65%.
- Moderna reaffirmed guidance for up to 10% revenue growth in 2026 based on its recent 10-Q filing.
- The company is advancing a diverse pipeline including T-cell engagers, an in-vivo CAR-T program, and a personalized cancer vaccine.
- Moderna stock has gained 45% over the past month while Merck added only 7% and Pfizer fell 6%.
- Year-to-date performance shows Moderna up 130% against Merck's 21% gain and Pfizer's 3% decline.
- Jefferies analyst raised its price target to $53, signaling continued interest in the company's potential.
Risk Factors
- The consensus analyst price target is $43.45, which is well below the current trading price of $68.
- Moderna stock trades at a forward P/E ratio of 23x on still-uncertain forward earnings.
- Recent insider transactions show a net selling trend with 75 recent deals tilting toward sales.
- Leerink has a price target near $24 and Morgan Stanley near $33, indicating the stock is running ahead of Street positioning.
- Pfizer's Comirnaty revenue fell 59% to $232 million in Q1 2026, underscoring reliance on non-COVID portfolios.
- The sell-side consensus remains cautious with 16 Hold ratings against a smaller cluster of Buys and Sells.
Moderna Inc. (NASDAQ: MRNA) shares surged approximately 6.21% on Tuesday, June 23, 2026, driven by a unanimous FDA advisory committee vote favoring its mRNA-1010/mFLUSIVA seasonal flu vaccine for adults aged 50 and older. The stock climbed from roughly $47 to $63 over the preceding month, reflecting strong momentum as investors pivot away from post-COVID concerns toward next-generation flu and oncology franchises. This regulatory milestone supports the company's Biologics License Application ahead of the August 5, 2026 PDUFA deadline.
Despite the positive catalysts, Moderna continues to report significant financial losses with quarterly revenue of $389M and a net loss of $1.34B for the quarter. Gross margins remain low at 22.6%, and EBITDA is negative $1.28B, indicating heavy ongoing R&D and operating expenditures. However, the company maintains a robust balance sheet with $5.2B in cash and short-term investments against total liabilities of $4.08B, providing ample liquidity to fund its expansion plans and restructuring efforts.
Management announced a strategic restructuring to support three commercial franchises across vaccines, oncology, and rare diseases, aiming for multiple launches between 2027 and 2028. Concurrently, Moderna is expanding its European footprint by investing in German manufacturing sites, including facilities previously operated by BioNTech. Analysts like Jefferies maintain a Hold rating with a $45 price target, noting that meaningful flu revenues are expected to ramp up starting in 2027, potentially reaching $750M in U.S. sales by 2030.
The stock's recent performance is attributed to the intersection of regulatory approval signals, corporate restructuring, and aggressive capacity build-out. Upcoming events include Moderna's Investor Science Day on June 25, 2026, where the company plans to showcase new programs leveraging mRNA technology combined with AI and robotics. Traders are closely monitoring these developments as the narrative shifts toward diversification beyond its COVID legacy.
📈 Moderna stock rose 6.21% to $63.08 on positive regulatory news.
✅ FDA voted unanimously for mRNA-1010 flu vaccine in adults 50+.
💰 Revenue hit $389M quarterly with $5.2B cash against $4.08B liabilities.
🔄 Restructuring supports vaccines, oncology, and rare disease launches by 2027–2028.
🇩🇪 Company invests in German manufacturing sites to expand European footprint.
📈 Moderna stock jumped 6.21% on Tuesday, June 23, 2026, rising from a low of $58.70 to close near $63.08 following positive regulatory and corporate news.
✅ The FDA advisory committee voted unanimously (9-0) that the mRNA-1010/mFLUSIVA flu vaccine has a favorable benefit-risk profile for adults aged 50–64 and 65+.
📅 This regulatory vote supports the Biologics License Application ahead of the August 5, 2026 PDUFA deadline for full approval in the U.S.
💰 Moderna reported quarterly revenue of $389M with trailing revenue of $1.94B, though it posted a net loss of $1.34B and EBITDA of -$1.28B.
🛡️ The company holds a strong balance sheet with $5.2B in cash, equivalents, and short-term investments against total liabilities of $4.08B.
🔄 Management announced a restructuring to support three commercial franchises preparing for launches in vaccines, oncology, and rare diseases in 2027–2028.
🇩🇪 Moderna plans to invest in German manufacturing sites, including facilities previously operated by BioNTech, to expand its European footprint.
📉 Analyst Jefferies reiterated a Hold rating with a $45 price target, estimating U.S. flu and combo sales could reach roughly $750M by 2030.
🔬 The upcoming June 25, 2026 Investor Science Day will feature new programs combining mRNA technology with AI and robotics for flu, oncology, and rare disease.
📊 Gross margins stand at 22.6% while EBIT margins are -140%, reflecting heavy R&D and operating spend despite the strengthening stock chart.
Bullish Signals
- FDA voted 9-0 to support Moderna's flu vaccine, reducing regulatory risk.
- Stock surged 34% from $47 to $63, showing strong investor confidence.
- Company holds $5.2B cash against $4.08B liabilities for ample liquidity.
- New three-franchise model signals strategic shift beyond the COVID one-hit-wonder.
- German manufacturing expansion builds independent global capacity for future vaccines.
Risk Factors
- Quarterly net income loss of -$1.34B.
- Gross margins low at 22.6%.
- EBIT margins negative at -140%.
- Free cash flow loss of -$692M.
Bullish Signals
- The FDA advisory committee voted unanimously (9-0) to support Moderna's mRNA-1010/mFLUSIVA flu vaccine, significantly reducing regulatory risk for the upcoming PDUFA deadline.
- Moderna's stock price surged over 34% in less than a month, climbing from $47 to $63, indicating strong investor confidence in the company's strategic pivot.
- The company possesses a substantial cash cushion of $5.2B against $4.08B in total liabilities, providing ample liquidity to fund restructuring and expansion without immediate distress.
- Management's announcement of a new three-franchise operating model signals a clear strategic shift away from being a one-hit-wonder post-COVID company.
- Expansion into German manufacturing sites demonstrates a commitment to building independent global capacity ahead of a broader product wave in vaccines and oncology.
Risk Factors
- Moderna continues to operate at a significant loss with quarterly net income from continuing operations at -$1.34B and EBITDA of -$1.28B.
- Gross margins are low at 22.6% and EBIT margins are steeply negative at -140%, reflecting heavy ongoing R&D and operating expenditures that pressure profitability.
- Free cash flow remains negative at approximately -$692M for the quarter, indicating continued high burn rates despite strong cash reserves.
Moderna, Inc. (MRNA) is a biotechnology company that transitioned from a platform-stage entity to a commercial vaccine producer following the global success of its COVID-19 vaccine. The company leverages messenger RNA technology to direct cells in producing proteins for immune responses or addressing disease biology across infectious diseases, oncology, and rare genetic conditions.
The article provides a technical and fundamental snapshot of MRNA as of June 19, 2026. Analyst sentiment is currently mixed with 64% of analysts rating the stock as a Hold, while insider selling has been the primary negative factor over the last 90 days, with net sales of approximately $6.2M.
Despite the insider selling, technical indicators present a strongly bullish outlook. The stock price trades above both the 50-day and 200-day moving averages, supported by positive MACD momentum and a bullish Relative Strength Index (RSI). No meaningful insider purchases were recorded during the recent period.
🧬 Moderna develops mRNA medicines for infectious diseases, oncology, and rare disorders.
📉 64% of analysts rate the stock as a Hold.
💸 Insiders net sold $6.2M in stock over the last 90 days.
📈 Technical signals show strong bullish momentum above key moving averages.
🚀 MACD and RSI indicators support a positive long-term trend.
🧬 Moderna utilizes mRNA technology to develop medicines for infectious diseases, oncology, and rare genetic disorders.
📉 Analyst sentiment is mixed with 64% of analysts currently rating the stock as a Hold.
💸 Insiders were net sellers of approximately $6.2M in Moderna stock over the last 90 days.
📈 Technical signals are strongly bullish with the price trading above key moving averages.
🚀 MACD momentum and RSI indicators currently support a positive long-term trend for the stock.
Bullish Signals
- Stock trades above 50-day and 200-day moving averages.
Risk Factors
- 64% of analysts rate stock as Hold.
- $6.2M net insider sales in last 90 days.
- No recent insider purchases recorded.
Bullish Signals
- Technical indicators show strong bullish momentum, with the stock price trading above both the 50-day and 200-day moving averages.
- MACD momentum is supportive, indicating continued upward pressure on the share price.
- The Relative Strength Index (RSI) is currently in a bullish configuration, suggesting positive market sentiment.
Risk Factors
- Analyst sentiment is mixed, with a majority of analysts (64%) rating the stock as a Hold rather than Buy.
- Insider selling has been the main negative factor, with net sales of approximately $6.2M recorded over the last 90 days.
- No meaningful insider purchases were recorded recently, which may signal a lack of confidence from company insiders.
Moderna Inc.'s mRNA-based influenza vaccine has received a recommendation for approval from an external advisory committee of the US Food and Drug Administration (FDA). This development marks a significant positive milestone for the biotechnology company, which has faced scrutiny regarding this specific product line at the regulatory agency.
The vote represents a notable shift in FDA stance, suggesting a reversal of previous controversial decisions made under prior leadership. The article highlights that similar reversals are occurring across other drug approvals, citing UniQure NV's Huntington's disease gene therapy as a recent example where the FDA quickly moved from recommending new trials to allowing approval based on existing data.
While this advisory committee vote is not the final regulatory decision, it serves as a major victory for Moderna and indicates a more favorable environment for its mRNA technology platform moving forward. The outcome underscores the company's ability to navigate regulatory hurdles after facing significant challenges with its flu vaccine candidate.
📈 FDA advisory committee recommends Moderna mRNA flu vaccine.
🔄 FDA reverses prior controversial decisions under previous leadership.
🧬 Recommendation validates Moderna's mRNA technology platform.
📅 UniQure Huntington's gene therapy approved days earlier.
⚖️ Rapid reversal significant for biotech investors after lengthy trial demands.
📈 Moderna Inc.'s mRNA influenza vaccine was recommended for approval by an FDA advisory committee.
🔄 This vote signals a major turnaround at the FDA, which is reportedly backing off from controversial decisions made under previous leadership.
🧬 The recommendation validates the company's mRNA technology platform despite prior contentious history with the agency.
📅 Recent context includes UniQure NV receiving approval for Huntington's disease gene therapy just days after the Moderna vote.
⚖️ The FDA previously recommended lengthy new trials for similar therapies, making this rapid reversal significant for biotech investors.
Bullish Signals
- FDA advisory committee recommends approval for Moderna's mRNA flu vaccine.
- Favorable FDA stance shift eases future regulatory hurdles for Moderna.
- Resolves previous contentious issues surrounding Moderna's flu vaccine product.
Bullish Signals
- Moderna Inc. has secured a major regulatory victory with an FDA advisory committee recommending approval for its mRNA flu vaccine.
- The vote indicates a favorable shift in the FDA's stance on Moderna's technology platform, potentially easing future regulatory hurdles.
- This development resolves previous contentious issues surrounding the company's flu vaccine product line.
Moderna (MRNA) stock has surged for a fifth consecutive day following the publication of FDA briefing documents indicating that immunogenicity data from its mFlusiva flu shot may support effectiveness in adults aged 65 and older. This represents a significant regulatory shift, as the FDA had previously rejected the application due to concerns about trial design, specifically the lack of a preferred higher-dose control arm for the elderly population.
The company successfully amended its application to address these initial concerns, leading to a favorable tone in the latest briefing documents ahead of an independent advisory panel meeting scheduled for Thursday. The panel will vote on whether mFlusiva's benefits outweigh risks for adults 50 and older, with a final FDA decision expected by August 5. If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine in the United States.
Despite some noted limitations, such as the vaccine being studied during only one flu season and the exclusion of immunocompromised or very frail older adults from trials, Moderna has agreed to conduct an additional study in the 65-plus age group if approval is granted for that specific population. Analyst Andrew Tsai from Jefferies views the assessment positively, projecting combined U.S. sales of $750 million for flu and COVID-flu combo vaccines by 2030.
Beyond the flu vaccine milestone, Moderna is gaining momentum with recent EU approval for mCOMBRIAX, its first-of-its-kind flu-plus-COVID combination vaccine globally. The company also appointed Ester Banque as Chief Commercial Officer to lead upcoming product launches. Investors are increasingly optimistic about a multi-product future, with potential pivotal data readouts for cancer therapy Intismeran and rare disease programs expected in 2026.
📈 Moderna stock rises after FDA documents support mFlusiva for adults 65+.
🔄 FDA reverses rejection following Moderna's trial design amendment for older adults.
🗓️ Advisory panel votes on mFlusiva; final decision expected by August 5.
💉 Approval would make mFlusiva the first mRNA seasonal flu vaccine in US.
⚠️ FDA notes study limitations including single-season data and excluded frail patients.
📈 Moderna stock surges for a fifth straight day after FDA staff reviewers publish briefing documents suggesting mFlusiva flu shot data supports effectiveness in adults 65 and older.
🔄 The FDA reversed its initial rejection of the flu vaccine application after Moderna agreed to amend its trial design regarding the control arm for patients 65 and over.
🗓️ An independent advisory panel will vote on mFlusiva benefits versus risks for adults 50 and older, with a final FDA decision expected by August 5.
💉 If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine in the United States.
📊 Jefferies analyst Andrew Tsai projects $750 million in combined U.S. flu and COVID-flu combo vaccine sales by 2030.
⚠️ FDA staff noted limitations including study during only one flu season and exclusion of immunocompromised or very frail older adults from trials.
🔬 Moderna agreed to run an additional study in the 65-plus age group if approval is granted for that population.
🌍 The company recently received EU approval for mCOMBRIAX, its flu-plus-COVID combination vaccine, marking the first of its kind globally.
👩💼 Moderna appointed Ester Banque as new Chief Commercial Officer to lead upcoming product launches globally.
🚀 Investors are optimistic about a multi-product future with potential pivotal data readouts for cancer therapy Intismeran and rare disease programs expected in 2026.
Bullish Signals
- FDA documents suggest favorable review of mFlusiva flu vaccine.
- Moderna reversed FDA rejection after amending trial design.
- mFlusiva would be first mRNA-based seasonal flu vaccine in US.
- Jefferies projects $750 million combined sales by 2030.
- EU approved mCOMBRIAX, first global flu-plus-COVID combo vaccine.
- Ester Banque appointed Chief Commercial Officer for launches.
- Pivotal cancer and rare disease data expected in 2026.
Risk Factors
- Limited to one flu season study.
- Excluded immunocompromised and frail older adults.
- FDA notes trial design and population limits.
Bullish Signals
- Moderna stock has gained meaningfully over five trading sessions following the publication of FDA briefing documents that suggest a favorable review of its mFlusiva flu vaccine.
- The FDA reversed its initial rejection of the flu vaccine application after Moderna amended its trial design, signaling a positive shift in regulatory stance.
- Approval of mFlusiva would establish it as the first mRNA-based seasonal flu vaccine in the United States, creating a unique market position.
- Analyst Andrew Tsai from Jefferies projects $750 million in combined U.S. sales for flu and COVID-flu combo vaccines by 2030.
- Moderna recently secured EU approval for mCOMBRIAX, becoming the first company globally to receive approval for a flu-plus-COVID combination vaccine.
- The appointment of Ester Banque as Chief Commercial Officer strengthens the company's leadership team for upcoming global product launches.
- Future pivotal data readouts for cancer therapy Intismeran and rare disease programs are expected in 2026, suggesting a robust pipeline beyond vaccines.
Risk Factors
- The mFlusiva vaccine has only been studied during one flu season, which may limit the generalizability of its effectiveness data.
- Immunocompromised and very frail older adults were excluded from the trials for mFlusiva, leaving efficacy in these high-risk groups unproven.
- The FDA briefing documents explicitly note limitations regarding the trial design and patient population included in the current data.
Moderna (MRNA) shares surged 9% today, extending a remarkable 94% gain year-to-date to trade near $57. This performance significantly outpaces peers Pfizer (PFE), which is up 4%, and Novavax (NVAX), which is up 41%. The rally is driven by corporate restructuring rather than new clinical data, as the company reorganizes its leadership to prepare for a major wave of product launches scheduled for 2027 and 2028.
The restructuring involves expanding President Stephen Hoge's role to oversee R&D, manufacturing, and commercial operations across three franchises, signaling a shift toward commercial scale. This operational backbone aligns with plans to launch up to three products by 2027-2028, including a flu-plus-COVID combination vaccine (mCOMBRIAX), a seasonal flu vaccine, and a norovirus vaccine. The company recently received EU approval for mCOMBRIAX and faces a key PDUFA decision on its seasonal flu candidate, mRNA-1010, on August 5.
Despite the strong stock performance, Moderna faces headwinds including a recent $878 million non-recurring litigation charge related to an Arbutus/Genevant patent settlement, which widened its Q1 2026 GAAP loss to $1.34 billion. Analyst sentiment remains cautious with an average one-year price target of $37 and a consensus 'Reduce' rating. The stock is still down 74% from its pandemic-era highs, framing the current rally as a rebound rather than a return to previous peaks.
Key upcoming events include an FDA advisory committee vote on June 18 regarding mFlusiva for adults 50 and older. A constructive readout could further support the stock, while a mixed verdict might test whether the 94% YTD gain is fully priced in. Investors are advised to monitor whether MRNA holds the $50 support level through these critical regulatory milestones before making position adjustments.
📈 Moderna stock rose 9%, extending a 94% year-to-date gain.
✅ EU approved mCOMBRIAX, the world's first flu-plus-COVID vaccine.
⚖️ Q1 2026 GAAP loss widened to $1.34 billion due to charges.
📉 Wall Street holds a 'Reduce' rating with a $37 price target.
🔍 FDA advisory vote on mFlusiva scheduled for June 18.
📈 Moderna stock jumped 9% today, extending a 94% year-to-date gain and outperforming peers Pfizer (+4%) and Novavax (+41%).
🏗️ The company announced a leadership restructuring to prepare for up to three product launches by 2027-2028, including flu-plus-COVID and norovirus vaccines.
✅ EU approval was granted for mCOMBRIAX, the world's first flu-plus-COVID combination vaccine, reinforcing the commercialization narrative.
📅 A critical PDUFA decision for the seasonal flu candidate mRNA-1010 is scheduled for August 5.
⚖️ Q1 2026 included an $878 million non-recurring litigation charge tied to the Arbutus/Genevant patent settlement.
📉 Wall Street maintains a cautious outlook with an average one-year price target of $37 and a consensus 'Reduce' rating.
🔍 An FDA advisory committee vote on mFlusiva for adults 50+ is scheduled for June 18, serving as a key near-term catalyst.
📊 Moderna's Q1 2026 GAAP loss widened to $1.34 billion due to the litigation charge and declining revenue from Comirnaty (-59%) and Paxlovid (-63%).
Bullish Signals
- Moderna stock up 94% YTD, beating rivals.
- Leadership shift targets commercial scale by 2027-2028.
- EU approved mCOMBRIAX; mRNA-1010 PDUFA Aug 5.
- Pipeline diversifies with flu-COVID combo and norovirus vaccines.
Risk Factors
- Q1 2026: $878M non-recurring litigation charge recorded.
- Comirnaty revenue down 59%; Paxlovid down 63% YoY.
- Widened GAAP loss of $1.34 billion in Q1 2026.
- Analysts rate 'Reduce' with average price target of $37.
- Stock down 74% from pandemic-era peak highs.
Bullish Signals
- Moderna stock has delivered a remarkable 94% return year-to-date, significantly outperforming major vaccine competitors Pfizer and Novavax.
- The leadership restructuring signals a strategic shift toward commercial scale, preparing the company for multiple product launches in 2027-2028.
- Regulatory momentum is strong with recent EU approval for mCOMBRIAX and an upcoming PDUFA decision for mRNA-1010 on August 5.
- The pipeline includes diverse candidates such as a flu-plus-COVID combo vaccine, seasonal flu vaccine, and norovirus vaccine, diversifying future revenue streams.
Risk Factors
- Moderna recorded a $878 million non-recurring litigation charge in Q1 2026 related to the Arbutus/Genevant patent settlement.
- Revenue from key products is declining, with Comirnaty down 59% and Paxlovid down 63% year-over-year in Q1 2026.
- The company reported a widened GAAP loss of $1.34 billion for the first quarter of 2026.
- Analyst consensus remains cautious with an average one-year price target of $37 and a 'Reduce' rating.
- The stock is still down 74% from its pandemic-era peaks, indicating significant downside from historical highs.
Moderna has launched Moderna Direct, a new direct-to-healthcare ordering platform powered by FFF Enterprises' proprietary BioSupply® ecommerce technology. This strategic partnership allows Moderna to bypass traditional distribution channels and offer its customers a customized, branded experience for accessing its product portfolio. The launch represents a significant step forward in how Moderna supports its business customers, with the company citing momentum for future innovation and expanded self-service capabilities.
Robert Keith, FFF's senior vice president of customer experience and communication, highlighted the rapid implementation and scalable foundation built to enhance the customer interface. Matt Block, U.S. general manager at Moderna, praised FFF as a strong collaborator committed to delivering value to customers. The platform is designed to meet the needs of manufacturing partners and enable direct-to-healthcare business models, leveraging FFF's 38-year history as a specialty pharmaceutical distributor.
Patrick M. Schmidt, CEO of FFF Enterprises, expressed honor in offering this capability as part of their suite of services for pharmaceutical manufacturing and healthcare provider customers. The company notes its investment in best-in-class technologies and cybersecurity solutions to support nationwide commerce. This collaboration underscores the growing trend of manufacturers utilizing specialized distributors' technology platforms to streamline direct sales and improve customer experiences in the specialty pharmaceutical sector.
🚀 Moderna launches "Moderna Direct" platform for streamlined healthcare product access.
🤝 Solution powered by FFF Enterprises' proprietary BioSupply® e-commerce technology.
🎨 Customized branded experience enhances ordering process and customer innovation.
🔄 Enables direct-to-healthcare models bypassing traditional distribution channels.
📞 Contact Michelle Valenzuela at FFF for service inquiries.
🚀 Moderna has launched a new direct-to-customer platform called "Moderna Direct" to streamline product access for healthcare customers.
🤝 The platform is powered by FFF Enterprises, Inc., a specialty pharmaceutical distributor based in Temecula, California.
💻 The solution utilizes BioSupply®, which is FFF's proprietary e-commerce platform built on a scalable foundation.
🎨 The new site features a customized, Moderna-branded experience designed to enhance the ordering process for customers.
🗣️ Robert Keith, SVP of customer experience at FFF, stated that the collaboration allows them to build on a strong foundation to elevate the customer experience.
🚀 Matt Block, U.S. general manager at Moderna, described the launch as an important step forward in supporting their customers and driving future innovation.
🏢 FFF Enterprises has been operating since 1988 and is a privately held, multibillion-dollar healthcare technology company.
🔄 The new platform enables direct-to-healthcare business models that bypass traditional distribution channels for manufacturing partners.
🛡️ FFF's nationwide commerce network utilizes world-class technology and cybersecurity solutions to support its partners.
📞 For inquiries regarding the e-commerce services, interested parties should contact Michelle Valenzuela, VP of marketing & communications at FFF.
Bullish Signals
- Moderna selected FFF Enterprises' BioSupply® platform for its new Direct site.
- Launch supports customers and drives innovation in Moderna's direct business model.
- FFF brings 38 years of growth with scalable, intuitive interface enhancements.
- Moderna Direct offers streamlined access via a customized, branded experience.
- Partnership leverages world-class tech, cybersecurity, and nationwide distribution networks.
Bullish Signals
- Moderna has selected FFF Enterprises' proprietary BioSupply® ecommerce platform to power its new Moderna Direct site, enhancing the ordering experience for customers.
- The launch represents an important step forward in supporting customers and creates momentum for future innovation within Moderna's direct business model.
- FFF Enterprises brings 38 years of growth and a strong, scalable foundation to this collaboration, ensuring intuitive interface enhancements and expanded self-service capabilities.
- Moderna Direct provides streamlined access to the product portfolio through a customized, Moderna-branded experience that bypasses traditional channels.
- The partnership leverages world-class technology and cybersecurity solutions supported by a nationwide network of distribution and infusion pharmacy locations.
Risk Factors
- No negative aspects or risks identified in the provided article; it is a positive press release announcing a new partnership and platform launch.
On May 21, 2026, Flagship Pioneering, LLC executed a matched exercise-and-sell transaction involving Moderna (MRNA) shares. The entity exercised stock options to acquire 9,263 shares at an exercise price of $19.15 per share. Immediately following the acquisition, Flagship Pioneering sold the exact same quantity of shares on the open market at an average price of $46.84 per share.
The transaction was conducted by entities associated with Moderna director Noubar Afeyan. Following the sale, Flagship Pioneering retained a small indirect holding of 3,924 shares. The filing details significant direct and indirect holdings held by Noubar Afeyan and related Flagship Ventures funds, totaling millions of shares, while noting that Afeyan disclaims full beneficial ownership of shares held by the Flagship entities except to the extent of his pecuniary interest.
This Form 4 filing reports a standard exercise-and-sell sequence where an insider entity converts vested options into cash by selling the underlying stock. The sale price of $46.84 represents a substantial premium over the $19.15 option strike price, indicating the shares were purchased at a discount relative to their market value at the time of the transaction.
📅 Flagship Pioneering exercised options for 9,263 Moderna shares on May 21, 2026.
💰 Shares were immediately sold at $46.84 per share for a net profit of $27.69.
👤 Noubar Afeyan controls entities holding over 2 million direct and 4.6 million indirect shares.
⚖️ Afeyan disclaims full beneficial ownership, retaining interest only via his pecuniary stake.
📅 On May 21, 2026, Flagship Pioneering exercised options for 9,263 Moderna shares at $19.15 per share.
💰 The same entity immediately sold those 9,263 shares on the open market at an average price of $46.84 per share.
👤 Noubar Afeyan is the ultimate control person of the reporting entities and holds over 2 million direct shares.
🏦 Related Flagship Ventures funds hold additional indirect stakes totaling approximately 4.6 million shares combined.
📉 The transaction resulted in a net profit per share of roughly $27.69 before fees due to the spread between exercise and sale prices.
⚖️ Afeyan disclaims full beneficial ownership of Flagship entity holdings, retaining interest only to the extent of his pecuniary stake.
Bullish Signals
- Insider sold at $46.84 premium vs $19.15 strike.
- Noubar Afeyan owns over 2.2 million shares directly.
- Matched exercise-and-sell is neutral liquidity, not distress.
Risk Factors
- Sale of 9,263 shares increases supply and may lower price.
- Afeyan's limited disclosure reduces visibility into his total exposure.
Bullish Signals
- The insider sold shares at a significant premium to the option strike price ($46.84 vs $19.15), suggesting confidence in the stock's value relative to the cost basis.
- Noubar Afeyan maintains substantial direct ownership of over 2.2 million shares, indicating continued skin in the game despite the sale activity.
- The matched exercise-and-sell transaction is a neutral liquidity event rather than a signal of distress or lack of conviction.
Risk Factors
- The open-market sale of 9,263 shares increases immediate supply, which can exert short-term downward pressure on the stock price.
- Afeyan's disclaimer of beneficial ownership for Flagship entity holdings limits transparency regarding his total economic exposure to the company.
The FDA scheduled a public advisory committee meeting for June 18 to review Moderna's experimental mRNA flu vaccine, Mflusiva, examining its safety and effectiveness before a potential approval later in August. This meeting follows an initial rejection of the application in February by former FDA vaccines chief Vinay Prasad, despite objections from agency career staff, after which the agency agreed to reconsider the product following discussions with the company. Approval could mark a significant milestone as Moderna's shot would be the first flu vaccine utilizing mRNA technology.
Moderna is seeking this new growth avenue as its stock has declined significantly from pandemic-era highs due to falling demand for its Spikevax COVID-19 vaccine. The proposed Mflusiva vaccine faces scrutiny because it utilizes mRNA technology, which has been criticized by Health and Human Services Secretary Robert F. Kennedy Jr., who currently oversees the FDA. The upcoming review aims to determine if the standalone flu shot can help reignite growth for the biopharmaceutical company after its reliance on pandemic-era vaccines wanes.
🩺 FDA reviews Moderna's experimental mRNA flu vaccine at a June 18 advisory meeting.
⏳ Approval is required before standalone distribution can begin in August.
🔄 The agency reverses a February rejection following earlier regulatory objections.
🧬 Mflusiva marks the first influenza vaccine developed using mRNA technology.
🩺 The FDA has scheduled a public advisory committee meeting for June 18 to review Moderna's experimental flu vaccine, Mflusiva.
🔬 This gathering will feature independent scientific and public-health experts evaluating the vaccine's safety and effectiveness.
⏳ Moderna is awaiting regulatory approval to begin standalone distribution of this flu shot later this August.
🔄 The agency reversed a February rejection of Mflusiva after initial objections from then-acting FDA vaccines chief Vinay Prasad.
📉 Moderna's stock prices have dropped significantly due to declining demand for its pandemic-era Spikevax product.
🧬 Mflusiva will be the first influenza vaccine developed using mRNA technology, a format currently criticized by HHS Secretary Robert F. Kennedy Jr.
Bullish Signals
- FDA meeting scheduled June 18 for Mflusiva review.
- Agency pivoted from February rejection to convene scientific review.
- Moderna positioned for standalone flu approval by late August.
- Mflusiva would be the first mRNA flu vaccine.
Risk Factors
- FDA rejected initial standalone flu shot application due to Vinay Prasad.
- HHS Secretary RFK Jr. criticizes mRNA technology and oversees FDA.
- Moderna stock dropped from pandemic highs amid falling Spikevax demand.
- August regulatory approval critical; June 18 meeting could delay timeline.
Bullish Signals
- The FDA has scheduled a public advisory committee meeting for June 18 to review Moderna's experimental influenza vaccine, Mflusiva.
- After an initial rejection in February due to objections from the vaccines chief, the agency pivoted and agreed to convene this scientific review.
- Moderna is positioned to receive standalone flu shot approval later this August if the review is successful.
- Mflusiva would be the first flu vaccine made with mRNA technology, offering a new technological platform for the company.
Risk Factors
- Moderna's initial application for its standalone flu shot was rejected in February at the behest of Vinay Prasad, the FDA's vaccines chief, indicating significant regulatory hurdles ahead.
- The proposed Mflusiva vaccine faces criticism from Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the FDA and has publicly criticized mRNA technology.
- Moderna's stock has already tumbled from pandemic-era highs due to falling demand for Spikevax, adding pressure before this new product launch.
- The company is facing a critical dependency on regulatory approval later in August, with the upcoming June 18 advisory committee meeting being a potential bottleneck that could delay or jeopardize the timeline.
